Share of the companies with an open-market insider purchase (no 10b5-1 plan) in the last 90 days.
Dollars directors and officers spent on open-market purchases, all companies together, last 90 days.
Dollars directors and officers received from open-market sales, all companies together, last 90 days.
Dollars bought minus sold on the open market by directors and officers, all companies together, last 90 days.
Companies the tracked conviction funds (Berkshire, Pershing Square, …) net bought in their latest 13F.
Conviction funds buying — top 20%Share of the companies whose stake the largest active managers raised in their latest 13F.
Share of the companies whose stake the largest active mutual funds and ETFs raised in their latest N-PORT.
Share of the companies whose revenue growth is faster than a quarter earlier.
Share of the companies whose operating margin is up over 3 years.
Median expected earnings growth in Hand of the Market's own model (HoM est.) (revenue-growth based).
Share of the companies with a return on invested capital of at least 10%.
Median shares sold short as % of shares outstanding (FINRA).
Heavily shorted — top 20%Ticker | Company | Quality checks | Revenue growth YoY | Op. margin change 3y | ROIC | Insiders buying (90d) | Insider $ bought (90d) |
|---|---|---|---|---|---|---|---|
| ELAN | Elanco Animal Health Inc | 2/2 | 10.2% | — | — | 5 | $1.47M |
| PFE | PFIZER INC | 2/3 | 2.6% | — | — | 3 | $2.96M |
| INDV | Indivior Pharmaceuticals, Inc. | 2/3 | 13.6% | — | 667.2% | 1 | $107.96K |
| NEOG | NEOGEN CORP | 1/5 | 6.5% | −6.3 pp | -0.2% | 1 | $4.37K |
| BMY | BRISTOL MYERS SQUIBB CO | 6/6 | 5.7% | +5.0 pp | 16.1% | — | — |
| EXEL | EXELIXIS, INC. | 6/6 | 10.6% | +31.6 pp | 49.1% | — | — |
| IDXX | IDEXX LABORATORIES INC /DE | 6/6 | 9.7% | +2.2 pp | 48.9% | — | — |
| JAZZ | Jazz Pharmaceuticals plc | 6/6 | 15.6% | +18.3 pp | 11.9% | — | — |
| LNTH | Lantheus Holdings, Inc. | 6/6 | 2.7% | +16.9 pp | 17.8% | — | — |
| ABBV | AbbVie Inc. | 5/6 | 10.2% | −4.8 pp | 21.0% | — | — |
| ABT | ABBOTT LABORATORIES | 5/6 | 13.0% | +0.5 pp | 6.8% | — | — |
| ADMA | ADMA BIOLOGICS, INC. | 5/6 | 2.0% | +51.8 pp | 37.4% | — | — |
| AMGN | AMGEN INC | 5/6 | 9.5% | −5.7 pp | 17.7% | — | — |
| ANIP | ANI PHARMACEUTICALS INC | 5/6 | 25.9% | +10.6 pp | 21.2% | — | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | 5/5 | 6.3% | +2.3 pp | 23.1% | — | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | 5/6 | 4.8% | +5.5 pp | 14.9% | — | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | 5/6 | 16.7% | −9.5 pp | 10.3% | — | — |
| TGTX | TG THERAPEUTICS, INC. | 5/6 | 70.3% | +824.4 pp | 15.7% | — | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | 4/6 | 5.4% | −8.6 pp | 7.6% | — | — |
| AMRX | Amneal Pharmaceuticals, Inc. | 4/5 | 9.9% | +6.1 pp | 17.6% | — | — |
| HALO | HALOZYME THERAPEUTICS, INC. | 4/6 | 47.7% | −3.7 pp | 19.9% | — | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | 4/4 | 39.5% | +14.6 pp | — | — | — |
| PCRX | Pacira BioSciences, Inc. | 4/6 | 6.2% | −4.5 pp | 2.0% | — | — |
| RGEN | REPLIGEN CORP | 4/6 | 11.9% | −10.7 pp | 2.5% | — | — |
| TECH | BIO-TECHNE Corp | 4/6 | 1.3% | −5.6 pp | 9.3% | — | — |
| ACAD | ACADIA PHARMACEUTICALS INC | 3/6 | 16.4% | +30.7 pp | 9.4% | — | — |
| ALKS | Alkermes plc. | 3/6 | 27.0% | −15.2 pp | 2.8% | — | — |
| ARQT | Arcutis Biotherapeutics, Inc. | 3/5 | 59.3% | +2719.9 pp | 9.2% | — | — |
| BIIB | BIOGEN INC. | 3/6 | 3.4% | −21.2 pp | 3.4% | — | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 3/6 | 19.9% | −0.7 pp | 0.8% | — | — |
| CORT | CORCEPT THERAPEUTICS INC | 3/6 | 31.7% | −22.3 pp | 1.1% | — | — |
| HRMY | Harmony Biosciences Holdings, Inc. | 3/4 | 30.3% | −5.4 pp | 28.7% | — | — |
| JNJ | JOHNSON & JOHNSON | 3/3 | 5.9% | — | — | — | — |
| LGND | LIGAND PHARMACEUTICALS INC | 3/6 | 33.7% | +30.1 pp | 7.2% | — | — |
| LQDA | Liquidia Corp | 3/4 | 1842.7% | +303.5 pp | — | — | — |
| MRK | Merck & Co., Inc. | 3/3 | 5.1% | — | — | — | — |
| PBH | Prestige Consumer Healthcare Inc. | 3/6 | 6.5% | +28.4 pp | 6.0% | — | — |
| PTCT | PTC THERAPEUTICS, INC. | 3/4 | 101.6% | +85.2 pp | — | — | — |
| PTGX | Protagonist Therapeutics, Inc | 3/4 | 3749.2% | — | 13.6% | — | — |
| SDGR | Schrodinger, Inc. | 3/4 | 7.5% | +26.6 pp | -294.9% | — | — |
| UTHR | UNITED THERAPEUTICS Corp | 3/4 | -1.9% | −7.1 pp | — | — | — |
| VCEL | Vericel Corp | 3/4 | 22.5% | +14.3 pp | — | — | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | 3/4 | 12.4% | −3.8 pp | — | — | — |
| ZTS | Zoetis Inc. | 3/3 | -0.2% | — | — | — | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | 2/3 | 171.0% | +36.6 pp | — | — | — |
| CYTK | CYTOKINETICS INC | 2/3 | -57.1% | +3797.1 pp | — | — | — |
| GILD | GILEAD SCIENCES, INC. | 2/4 | 10.2% | −39.1 pp | -5.7% | — | — |
| INVA | Innoviva, Inc. | 2/5 | 19.3% | −55.6 pp | 15.0% | — | — |
| KRYS | Krystal Biotech, Inc. | 2/3 | 24.1% | — | 21.2% | — | — |
| LLY | ELI LILLY & Co | 2/3 | 47.7% | — | — | — | — |
| OGN | Organon & Co. | 2/3 | -2.3% | — | — | — | — |
| RCUS | Arcus Biosciences, Inc. | 2/4 | -74.4% | +250.6 pp | -92.5% | — | — |
| SRPT | Sarepta Therapeutics, Inc. | 2/4 | -34.3% | +43.5 pp | -6.3% | — | — |
| MRNA | Moderna, Inc. | 1/4 | 2.1% | −153.8 pp | -46.6% | — | — |
| PRGO | PERRIGO Co plc | 1/4 | -3.2% | −41.4 pp | -22.8% | — | — |
| QDEL | QuidelOrtho Corp | 1/4 | 2.8% | −37.7 pp | -14.3% | — | — |
| ROIV | Roivant Sciences Ltd. | 1/3 | -33.6% | −6070.0 pp | — | — | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | 1/3 | 32.4% | −18.9 pp | — | — | — |
| VTRS | Viatris Inc | 1/5 | 4.9% | −7.8 pp | -0.3% | — | — |
| VIR | Vir Biotechnology, Inc. | 0/4 | 19582.5% | −28.4 pp | -31.4% | — | — |
| XNCR | Xencor Inc | 0/4 | 17.5% | −58.0 pp | -30.3% | — | — |